Comparative Effectiveness of Empagliflozin in the US

NCT03363464 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

230000

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Empagliflozin
DRUG: DPP-4 inhibitor
DRUG: GLP-1 receptor agonist

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]